Distinguished in Diabetic Ketoacidosis

Dr. Mark Clements

Pediatric Endocrinology
Children's Mercy Kansas City
2401 Gillham Rd, 
Kansas City, MO 
Distinguished in Diabetic Ketoacidosis
Children's Mercy Kansas City
2401 Gillham Rd, 
Kansas City, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Clements is a Pediatric Endocrinologist in Kansas City, Missouri. Dr. Clements is rated as a Distinguished provider by MediFind in the treatment of Diabetic Ketoacidosis. His top areas of expertise are Type 1 Diabetes (T1D), Low Blood Sugar, Diabetic Ketoacidosis, and Type 2 Diabetes (T2D).

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Diabetic Ketoacidosis.

Specialties
Pediatric Endocrinology
Licenses
Pediatric Endocrinology in MO
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

Children's Mercy Kansas City
2401 Gillham Rd, Kansas City, MO 64108
Other Locations
Office
5808 W 110th St, Leawood, KS 66211

Additional Areas of Focus

Dr. Clements has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Pediatric Growth Hormone Deficiency

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer)
Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer)
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Drug, Device
Study Drug: Verapamil
Study Phase: Phase 3
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Device
Study Phase: Not Applicable
An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years
An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years
Enrollment Status: Completed
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Glucagon
Study Phase: Phase 1
A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)
A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drug: Dulaglutide
Study Phase: Phase 3
An Interactive mHealth App for Better Glycemic Control in Parents of Young Kids With T1D
An Interactive mHealth App for Better Glycemic Control in Parents of Young Kids With T1D
Enrollment Status: Completed
Publish Date: March 11, 2022
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
Longitudinal Test of Adherence & Control in Kids New to Type 1 Diabetes & 5-9 Years Old
Longitudinal Test of Adherence & Control in Kids New to Type 1 Diabetes & 5-9 Years Old
Enrollment Status: Completed
Publish Date: February 11, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
Post Approval Study for Non-Adjunctive Use of Dexcom G5 and G6 CGM System for Diabetes Management
Post Approval Study for Non-Adjunctive Use of Dexcom G5 and G6 CGM System for Diabetes Management
Enrollment Status: Unknown
Publish Date: September 21, 2021
Intervention Type: Device
A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal Regulatory T-cells) in Adolescents With Recent Onset Type 1 Diabetes Mellitus (T1DM)
A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal Regulatory T-cells) in Adolescents With Recent Onset Type 1 Diabetes Mellitus (T1DM)
Enrollment Status: Completed
Publish Date: January 08, 2021
Intervention Type: Biological
Study Phase: Phase 2
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus
Enrollment Status: Active_not_recruiting
Publish Date: November 09, 2020
Intervention Type: Other, Biological
Study Drug: TOL-3021
Study Phase: Phase 2
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data
Enrollment Status: Completed
Publish Date: March 05, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 11 Less Clinical Trials

159 Total Publications

iCoDE-2 September 18, 2025 Steering Committee Final Meeting Summary Report.
iCoDE-2 September 18, 2025 Steering Committee Final Meeting Summary Report.
Journal: Journal of diabetes science and technology
Published: October 22, 2025
Similar Doctors
Distinguished in Diabetic Ketoacidosis
Dr. Ryan Mcdonough
Pediatric Endocrinology
Distinguished in Diabetic Ketoacidosis
Dr. Ryan Mcdonough
Pediatric Endocrinology
2401 Gillham Rd, 
Kansas City, MO 
 (0.1 miles away)
816-234-3000
Languages Spoken:
English
See accepted insurances

Ryan Mcdonough is a Pediatric Endocrinologist in Kansas City, Missouri. Dr. Mcdonough is rated as a Distinguished provider by MediFind in the treatment of Diabetic Ketoacidosis. His top areas of expertise are Type 1 Diabetes (T1D), Diabetic Ketoacidosis, Low Blood Sugar, and Addison's Disease.

Advanced in Diabetic Ketoacidosis
Dr. Michelle Knoll
Pediatric Endocrinology
Advanced in Diabetic Ketoacidosis
Dr. Michelle Knoll
Pediatric Endocrinology

Kansas Orthopedics And Sports Medicine A Division Of Stormont-Vail Hea

909 SW Mulvane St, 
Topeka, KS 
 (60.2 miles away)
785-600-3775
Languages Spoken:
English
See accepted insurances

Michelle Knoll is a Pediatric Endocrinologist in Topeka, Kansas. Dr. Knoll is rated as an Advanced provider by MediFind in the treatment of Diabetic Ketoacidosis. Her top areas of expertise are Diabetic Ketoacidosis, Type 1 Diabetes (T1D), Turner Syndrome, and Intersex.

Advanced in Diabetic Ketoacidosis
Dr. Sarah Lenihan
Pediatric Endocrinology
Advanced in Diabetic Ketoacidosis
Dr. Sarah Lenihan
Pediatric Endocrinology

Children's Mercy Clinics On Broadway

3101 Broadway Blvd, 
Kansas City, MO 
 (1.1 miles away)
816-960-8803
Languages Spoken:
English
See accepted insurances

Sarah Lenihan is a Pediatric Endocrinologist in Kansas City, Missouri. Dr. Lenihan is rated as an Experienced provider by MediFind in the treatment of Diabetic Ketoacidosis. Her top areas of expertise are Diabetic Hyperglycemic Hyperosmolar Syndrome, Diabetic Ketoacidosis, Addison's Disease, and Growth Hormone Deficiency (GHD).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Clements's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile